Nathan Lorde

University Hospitals Birmingham NHS Foundation Trust

United Kingdom

Research Interests

Explore related searches

Professors in United Kingdom

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (10)

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Collaborators (7)

Nicholas Gray

Sunshine Coast University Hospital

AUSTRALIA

View details

Tarekegn Geberhiwot

UNITED KINGDOM

View details

Farah E Latif

Clinical Lecturer

Cardiff University

UNITED KINGDOM

View details

Shivani Mahapatra

Clinical Teaching Fellow

NHS England

UNITED KINGDOM

View details

Se Won Oh

Associate professor

Seoul National University Hospital

SOUTH KOREA

View details

Rousseau Gama

University of Wolverhampton

UNITED KINGDOM

View details

Nuno Moreira Fonseca

Universidade do Porto Faculdade de Medicina

PORTUGAL

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Nathan Lorde

Research Interests

Explore related searches

Contact this professor

Articles (10)

Paraprotein-induced spurious hypercalcaemia: diagnostic pitfalls in two cases

Prevalence and detection of citrate contamination in clinical laboratory

High serum total vitamin B12 may mask biologically active B12 deficiency

Acquired haemoglobin F (HbF) in HbA1c analysis predating a diagnosis of myelodysplastic syndrome

Machine Learning for Patient-Based Real-Time Quality Control (PBRTQC), Analytical and Preanalytical Error Detection in Clinical Laboratory

Potassium ethylenediaminetetraacetic acid (kEDTA) sample cross-contamination: prevalence, consequences, identification, mechanisms, prevention and mitigation

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis.

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Impact of Variation between Assays and Reference Intervals in the Diagnosis of Endocrine Disorders

Collaborators (7)

Nicholas Gray

Tarekegn Geberhiwot

Farah E Latif

Shivani Mahapatra

Se Won Oh

Rousseau Gama

Nuno Moreira Fonseca

Make your next move.